These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 26086299)

  • 1. Universal Hepatitis C Eradication Prior to Liver Transplantation: We Can Do It, but Should We?
    Brown RS
    Am J Transplant; 2015 Jul; 15(7):1741-2. PubMed ID: 26086299
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-Effectiveness of New Direct-Acting Antivirals to Prevent Post-Liver Transplant Recurrent Hepatitis.
    Cortesi PA; Mantovani LG; Ciaccio A; Rota M; Mazzarelli C; Cesana G; Strazzabosco M; Belli LS
    Am J Transplant; 2015 Jul; 15(7):1817-26. PubMed ID: 26086300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hepatitis C: cost of eradication ].
    Nau JY
    Rev Med Suisse; 2014 Jan; 10(415):306-7. PubMed ID: 24624702
    [No Abstract]   [Full Text] [Related]  

  • 4. Antiviral therapy in liver transplant recipients: is SVR the only endpoint that matters?
    Kuo A; Terrault NA
    J Hepatol; 2007 Mar; 46(3):359-61. PubMed ID: 17223220
    [No Abstract]   [Full Text] [Related]  

  • 5. [Prophylaxis and treatment for recurrent hepatitis C virus after liver transplantation].
    Sugawara Y; Makuuchi M
    Nihon Shokakibyo Gakkai Zasshi; 2006 Jun; 103(6):626-30. PubMed ID: 16800284
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir+Ribavirin for US Post-Liver Transplant Recurrent Genotype 1 HCV.
    Saab S; Gonzalez YS; Huber C; Wang A; Juday T
    Liver Int; 2016 Apr; 36(4):515-21. PubMed ID: 26610059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Editorial commentary: Hepatitis C].
    Pár A
    Orv Hetil; 2015 May; 156(21):835. PubMed ID: 26038989
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation.
    Gambato M; Lens S; Navasa M; Forns X
    J Hepatol; 2014 Nov; 61(1 Suppl):S120-31. PubMed ID: 25443340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The economics of hepatitis C virus.
    Shah BB; Wong JB
    Clin Liver Dis; 2006 Nov; 10(4):717-34. PubMed ID: 17164114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribavirin in the treatment of recurrent hepatitis C after liver transplantation: difficult to manage but essential for success.
    Samuel D; Roche B
    J Hepatol; 2007 Jun; 46(6):988-91. PubMed ID: 17445936
    [No Abstract]   [Full Text] [Related]  

  • 11. A Guide to the Economics of Hepatitis C Virus Cure in 2017.
    Linas BP; Nolen S
    Infect Dis Clin North Am; 2018 Jun; 32(2):447-459. PubMed ID: 29778265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppression, liver injury and post-transplant HCV recurrence.
    Ciesek S; Wedemeyer H
    J Viral Hepat; 2012 Jan; 19(1):1-8. PubMed ID: 22187942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of a hypothetical hepatitis C vaccine compared to antiviral therapy.
    Massad E; Coutinho FA; Chaib E; Burattini MN
    Epidemiol Infect; 2009 Feb; 137(2):241-9. PubMed ID: 18631422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term ribavirin therapy for recurrent hepatitis C after liver transplantation.
    Aljumah AA; Cattral MS; Greig PD; Wanless IR; Krajden M; Hemming AW; Lilly LB; Levy GA
    Transplant Proc; 1997; 29(1-2):514. PubMed ID: 9123110
    [No Abstract]   [Full Text] [Related]  

  • 15. Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant.
    Punzalan CS; Barry C; Zacharias I; Rodrigues J; Mehta S; Bozorgzadeh A; Barnard GF
    Clin Transplant; 2015 Dec; 29(12):1105-11. PubMed ID: 26358816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
    Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
    Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
    Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
    World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis.
    Njei B; McCarty TR; Fortune BE; Lim JK
    Aliment Pharmacol Ther; 2016 Nov; 44(10):1090-1101. PubMed ID: 27640785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver stiffness 1 year after transplantation predicts clinical outcomes in patients with recurrent hepatitis C.
    Crespo G; Lens S; Gambato M; Carrión JA; Mariño Z; Londoño MC; Miquel R; Bosch J; Navasa M; Forns X
    Am J Transplant; 2014 Feb; 14(2):375-83. PubMed ID: 24410892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can hepatitis C virus be eliminated by 2030? Saudi Arabia as an example.
    Altraif I
    Saudi Med J; 2018 Aug; 39(8):842-845. PubMed ID: 30106425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.